40
Participants
Start Date
August 31, 2015
Primary Completion Date
October 31, 2016
Study Completion Date
December 31, 2016
ibalizumab
2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
Optimized Background Regimen (OBR)
All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
National Taiwan University Hospital, Taipei
ACRIA, New York
Montefiore Medical Center, The Bronx
Georgetown University School of Medicine, Washington D.C.
University of Maryland, Institute of Human Virology, Baltimore
Carolinas HealthCare System, Charlotte
AIDS Research Consortium of Atlanta, Atlanta
Orlando Immunology Center, Orlando
University of Miami, Miami
Gary Richmond, MD, PA, Fort Lauderdale
Triple O Research Institute, West Palm Beach
Midway Immunology and Research Center, Ft. Pierce
St. John Hospital and Medical Center, Southfield
Henry Ford Health Systems, Detroit
North Texas Infectious Disease Consultants, Dallas
Clinical Research PR, Inc, San Juan
Research Access Network, Houston
E-Da Hospital, Kaohsiung City
W King Health Care Group, Los Angeles
Southern California Permanente Medical Group, Los Angeles
Ruane Medical and Clinical Research Institute, Los Angeles
Charles R. Drew Univ. of Med. & Science Clinical and Translational Research Center, Los Angeles
Anthony Mills, MD, Inc., Los Angeles
AIDS Healthcare Foundation, Los Angeles
Long Beach Education and Research Consultants, Long Beach
Palmtree Clinical Research Inc., Palm Springs
Quest Clinical Research, San Francisco
Kaiser Foundation Research Institute, San Francisco
Yale University, New Haven
Circle Care Center, LLC, Norwalk
TaiMed Biologics Inc.
INDUSTRY